Filter Results:
(924)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Sort by
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- October 2002 (Revised June 2003)
- Background Note
New Frontiers in Target Discovery and Validation
By: Regina E. Herzlinger, Niv Caviar, Jon Chatterton and Andrea Lynn
Explains Immusol and Novartis's technology. View Details
Herzlinger, Regina E., Niv Caviar, Jon Chatterton, and Andrea Lynn. "New Frontiers in Target Discovery and Validation." Harvard Business School Background Note 303-054, October 2002. (Revised June 2003.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Brazil
Beer, Michael, and James Weber. "Merck Latin America (C): Brazil." Harvard Business School Case 401-031, March 2001. (Revised September 2002.)
- February 2000
- Case
Merck-Medco (B)
Keywords: Pharmaceutical Industry
Rangan, V. Kasturi. "Merck-Medco (B)." Harvard Business School Case 500-078, February 2000.
- February 1987 (Revised April 1987)
- Case
Eli Lilly and Co. (A)
By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
Bruns, William J., Jr. "Eli Lilly and Co. (A)." Harvard Business School Case 187-064, February 1987. (Revised April 1987.)
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details
Keywords: Projects; Groups and Teams; Operations; Management Teams; Product Development; Transition; Product Design; Business Startups; Business Plan; Product Launch; Competition; Service Operations; Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- September 1983 (Revised November 1984)
- Case
Syntex Laboratories (B)
The recommendations of the consultants require a number of assumptions and modifications to be implemented by Syntex Labs. Presents the initial implementation plan of the company. View Details
Keywords: Organizational Change and Adaptation; Strategic Planning; Salesforce Management; Pharmaceutical Industry
Clarke, Darral G. "Syntex Laboratories (B)." Harvard Business School Case 584-034, September 1983. (Revised November 1984.)
- July 28, 2004
- Article
Generic Dispensing and Substitution in Mail and Retail Pharmacies
By: Marta Wosinska and Robert S. Huckman
Wosinska, Marta, and Robert S. Huckman. "Generic Dispensing and Substitution in Mail and Retail Pharmacies." Health Affairs (July 28, 2004): W4–409 – W4–416.
- August 1995 (Revised June 1997)
- Case
Hillcrest Research Associates, Inc.
Hillcrest designs and administers testing procedures for drugs to determine whether they pass FDA specifications. As the company grows, it encounters problems with information technology and with the clinical research associates, who feel pressured to report more... View Details
Keywords: Growth Management; Information Technology; Health Testing and Trials; Pharmaceutical Industry
Barnes, Louis B. "Hillcrest Research Associates, Inc." Harvard Business School Case 496-021, August 1995. (Revised June 1997.)
- May 1992
- Teaching Note
Amgen, Inc.: Planning the Unplannable, Teaching Note
By: Nitin Nohria
Teaching Note for (9-492-052). View Details
Keywords: Pharmaceutical Industry
- 05 Mar 2001
- What Do You Think?
Fine Coupling: Can Human Resource Management Learn from Supply Chain Management?
Productivity will improve as the alternation of job assignments eliminates the 'indispensable' worker." Connie Luthy says, "I have practiced 'Just-In-Time' hiring ... in the pharmaceutical industry.... I have advised my client... View Details
Keywords: by James Heskett
- 10 Jan 2005
- Research & Ideas
Motivation and the Cross-Sector Alliance
medicines. Furthermore, Chile offers no reimbursements for pharmaceutical expenses, so this tends to add to customers' negative disposition." To respond to this situation, FASA considered a possible collaboration with the Fundación... View Details
- 10 Sep 2007
- Research & Ideas
High Note: Managing the Medici String Quartet
The panel consisted of Bob Frosch, who used to head NASA and R&D for GM; Vicki Sato, who was president of Vertex Pharmaceuticals and is now on the HBS faculty; and Peter Hanke, a conductor. These people have had a lot of experience... View Details
- 07 Aug 2009
- What Do You Think?
Why Can’t Americans Get Health Care Right?
above are numerous in a channel that includes, in your comments, food and tobacco producers of unhealthy products (Christy Hitchens, Tom Dolembo); lifestyle equipment and service providers; developers and manufacturers of high-cost View Details
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term... View Details
- 09 Feb 2016
- First Look
February 9, 2016
challenges as it seeks to continue its growth. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/816013-PDF-ENG Harvard Business School Case 316-010 The Allergan Board Under Fire (A) In 2014, the Allergan Inc. board of directors received a surprise takeover... View Details
Keywords: Sean Silverthorne
- 26 Sep 2006
- First Look
First Look: September 26, 2006
patient needs and working backwards to develop profitable solutions rather than starting with the government, pharmaceutical or healthcare industry or NGO. The examination is undertaken on two levels, a macro level that focuses on... View Details
Keywords: Sean Silverthorne